More valuable than platinum: First-line pembrolizumab in advanced stage non-small-cell lung cancer

Annals of Oncology

Volumn 28, Issue 4, 2017, Pages 685-687

  Zou, T ^a   Awad, M M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GENE MUTATION; HEPATITIS; HUMAN; METASTASIS POTENTIAL; MYOCARDITIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; LUNG TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLATINUM;

EID: 85019083667     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx083     Document Type: Editorial

References (17)

1. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833.
2. Pembrolizumab [package insert]. Kenilworth, NJ: Merck & Co 2016.
3. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
4. Hui R, Garon EB, Goldman JW et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol 2017; 28(4): 874-881.
5. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
6. Socinski M, Creelan B, Horn L et al. NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinumbased doublet chemotherapy (PT-DC) as first-line therapy for stage iv/ recurrent programmed death ligand 1 (PD-L1)positive NSCLC. Ann Oncol 2016; 27: LBA7_PR-LBA7_PR.
7. Gaule P, Smithy JW, TokiM et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol 2017; 3(2): 256-259.
8. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015; 348: 124-128.
9. Koyama S, Akbay EA, Li YY et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 2016; 76: 999-1008.
10. Skoulidis F, Byers LA, Diao L et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 2015; 5: 860-877.
11. Shin DS, Zaretsky JM, Escuin-Ordinas H et al. Primary resistance to PD- 1 blockade mediated by JAK1/2 mutations. Cancer Discov 2017; 7: 188-201.
12. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375: 819-829.
13. Van Allen EM, Golay HG, Liu Y et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol Res 2015; 3: 855-863.
14. Lizotte PH, Ivanova EV, Awad MM et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 2016; 1: e89014.
15. Gerdes MJ, Sevinsky CJ, Sood A et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 2013; 110: 11982-11987.
16. Tirosh I, Izar B, Prakadan SM et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016; 352: 189-196.
17. Ribas A, Robert C, Hodi FS et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015; 33: 3001-3001.